Role of B cells in generating anti-melanoma immunity in response to anti-PD-L1 antibody therapy

B cells potentially play a role in the immune response to melanoma, including during treatment with immune modulators. We profiled (transcriptome analysis) effects of anti-PD-L1 antibody therapy on gene expression in B16 melanoma tumors of B cells depleted and WT syngeneic mice. After 7 days of B16 tumors implantation, mice were treated or untreated with anti-PD-L1 antibody (every three days). Tumors from 4 mice in each group (B cells depleted treated with anti-PD-L1, WT treated with anti-PD-L1, B cells depleted untreated,WT untreated) were harvested 3 days after 3rd anti-PD-L1 treatment intratumoral injection of 3M-052 or control.